Amgen Inc. (AMGN)
| Market Cap | 142.29B |
| Revenue (ttm) | 28.19B |
| Net Income (ttm) | 6.72B |
| Shares Out | 535.92M |
| EPS (ttm) | 12.49 |
| PE Ratio | 21.26 |
| Forward PE | 13.33 |
| Dividend | $9.00 (3.39%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 1,733,175 |
| Open | 269.93 |
| Previous Close | 267.28 |
| Day's Range | 264.35 - 270.93 |
| 52-Week Range | 211.71 - 329.72 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 292.95 (+10.34%) |
| Earnings Date | May 2, 2024 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $292.95, which is an increase of 10.34% from the latest price.
News
Final Trades: Shell, 2-YR T-Note and Amgen
The Investment Committee give you their top stocks to watch for the second half.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Top three US healthcare stocks to buy in April
As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health. 1. Lilly (Eli) & Co.
Amgen wants in on the booming weight loss drug market — and it's taking a different approach
Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar...
Daily Dividend Report: GD, Amgen, American Express, Philip Morris, KAI
The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 20...
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
THOUSAND OAKS, Calif. , March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024.
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
THOUSAND OAKS, Calif. , Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m.
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
THOUSAND OAKS, Calif. , Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the mos...
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ion...
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
THOUSAND OAKS, Calif. , Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m.
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
THOUSAND OAKS, Calif. , Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m.
Amgen has 'a lot to prove' in the weight-loss drug category, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Amgen's obesity drug trial results.
Cramer's Stop Trading: Amgen
CNBC's Jim Cramer explains why he is keeping an eye on shares of Amgen.
Amgen's quarterly results top expectations despite Enbrel sales decline
Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts' expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel.
Amgen quarterly profit rises 15% as Horizon deal boosts results
Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Thera...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022.
Focus: Amgen taking different path to weight loss windfall
The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a unique ap...
Promising early data details on Amgen weight-loss drug published
Animal and early-stage human trial data for Amgen's experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the comp...
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after...
Pharma industry to get US government price cut proposals by Thursday
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's...
deCODE genetics: A sequence variant that increases risk of pregnancy loss
REYKJAVIK, Iceland , Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature St...
US FDA revises labeling on Amgen's drug to treat bone loss
The U.S. health regulator said on Friday it has revised the prescribing information on Amgen's drug to treat bone loss to include a boxed warning related to risk of severely low calcium level in certa...
Stocks This Week: Buy The Biotech Stocks: Amgen And Gilead
Two sets of reliable stock market cycles have topped. Technically, the market does not appear as weak as expected.